ATE541940T1 - Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo - Google Patents

Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo

Info

Publication number
ATE541940T1
ATE541940T1 AT02783361T AT02783361T ATE541940T1 AT E541940 T1 ATE541940 T1 AT E541940T1 AT 02783361 T AT02783361 T AT 02783361T AT 02783361 T AT02783361 T AT 02783361T AT E541940 T1 ATE541940 T1 AT E541940T1
Authority
AT
Austria
Prior art keywords
minicells
vectors
vitro
vivo
gene therapy
Prior art date
Application number
AT02783361T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Application granted granted Critical
Publication of ATE541940T1 publication Critical patent/ATE541940T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT02783361T 2001-10-15 2002-10-15 Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo ATE541940T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880101P 2001-10-15 2001-10-15
PCT/IB2002/004632 WO2003033519A2 (en) 2001-10-15 2002-10-15 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo

Publications (1)

Publication Number Publication Date
ATE541940T1 true ATE541940T1 (de) 2012-02-15

Family

ID=23282498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783361T ATE541940T1 (de) 2001-10-15 2002-10-15 Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo

Country Status (11)

Country Link
US (4) US20050222057A1 (de)
EP (2) EP2302063B1 (de)
JP (1) JP4458846B2 (de)
CN (2) CN102172406B (de)
AT (1) ATE541940T1 (de)
AU (1) AU2002347426B2 (de)
CA (2) CA2775218C (de)
DK (1) DK1446489T3 (de)
ES (2) ES2380612T3 (de)
PT (2) PT1446489E (de)
WO (1) WO2003033519A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ATE541940T1 (de) * 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
AU2002318168B2 (en) * 2002-02-25 2007-12-13 Vaxiion Therapeutics, Llc Minicell compositions and methods
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
WO2005047504A1 (en) * 2003-11-07 2005-05-26 The Board Of Trustees Of The University Of Illinois Induction of cellular senescence by cdk4 disruption for tumor suppression and regression
NZ547983A (en) * 2003-12-09 2009-05-31 Engeneic Molecular Delivery Pty Ltd Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
PL1718338T3 (pl) * 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
CN101072876B (zh) 2004-08-26 2012-11-28 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
CN101505768B (zh) * 2006-06-23 2013-11-06 因詹尼克分子递送控股有限公司 通过完整的死亡细菌细胞将药物、治疗性核酸和功能性核酸靶向递送至哺乳动物细胞
DK2865755T3 (en) 2007-03-30 2017-05-15 Engeneic Molecular Delivery Pty Ltd BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
KR101813824B1 (ko) * 2008-06-25 2017-12-29 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
IN2012DN03418A (de) * 2009-10-09 2015-10-23 Childrens Medical Center
AU2012217728B2 (en) 2011-02-15 2017-04-27 Vaxiion Therapeutics, Llc Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
SG11201403062YA (en) * 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
TWI737576B (zh) 2013-10-04 2021-09-01 澳大利亞商安珍尼Ｉｃ分子輸送私人有限公司 使用藥物裝載之雙特異性配位體標靶的微型細胞與干擾素-γ的組合式腫瘤治療
CN106999444B (zh) 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CA3039010A1 (en) 2016-10-06 2018-04-12 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
MX2019012845A (es) 2017-04-28 2019-11-28 Agrospheres Inc Composiciones y metodos para encapsular y administrar agroquimicos de forma escalable.
WO2018201160A1 (en) * 2017-04-28 2018-11-01 Agrospheres, Inc. Compositions and methods for enzyme immobilization
US11812743B2 (en) 2017-09-25 2023-11-14 Agrospheres, Inc. Compositions and methods for scalable production and delivery of biologicals
CA3100072A1 (en) 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Activating agents
WO2020021437A1 (en) 2018-07-23 2020-01-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
CN109540890A (zh) * 2018-11-27 2019-03-29 湖南品胜生物技术有限公司 一种基于细胞显微镜图像的dna定量分析方法
SG11202105822WA (en) * 2018-12-10 2021-06-29 Flagship Pioneering Innovations Vi Llc Achromosomal dynamic active systems
JP7548911B2 (ja) 2019-01-04 2024-09-10 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 腫瘍性疾患の治療のためのカプセル化グリコリピド抗原
US12357687B2 (en) 2020-03-24 2025-07-15 Engeneic Molecular Delivery Pty Ltd Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
AU2021292536A1 (en) * 2020-06-17 2023-02-02 Flagship Pioneering Innovations Vi, Llc. Methods for manufacturing ADAS
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US20240309390A1 (en) * 2021-06-01 2024-09-19 University Of Virginia Patent Foundation Minicells from highly genome reduced escherichia coli: cytoplasmic and surface expression of recombinant proteins and incorporation in the minicells
US12551550B2 (en) 2021-07-22 2026-02-17 Engeneic Molecular Delivery Pty Ltd Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5221479A (en) * 1991-02-15 1993-06-22 Fuji Photo Film Co., Ltd. Filtration system
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
EP0970212A1 (de) 1997-03-19 2000-01-12 ZymoGenetics, Inc. Zsig32, sekretierte speichelpolypeptide
IL157794A0 (en) * 2001-03-07 2004-03-28 Childrens Medical Center Method to screen peptide display libraries using minicell display
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ATE541940T1 (de) * 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
AU2002318168B2 (en) * 2002-02-25 2007-12-13 Vaxiion Therapeutics, Llc Minicell compositions and methods
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
NZ547983A (en) * 2003-12-09 2009-05-31 Engeneic Molecular Delivery Pty Ltd Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
US8772013B2 (en) * 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US7124679B2 (en) * 2004-08-25 2006-10-24 L&P Property Management Company Lower guide track for down packing press apparatus and method
CN101072876B (zh) * 2004-08-26 2012-11-28 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
CN101505768B (zh) * 2006-06-23 2013-11-06 因詹尼克分子递送控股有限公司 通过完整的死亡细菌细胞将药物、治疗性核酸和功能性核酸靶向递送至哺乳动物细胞

Also Published As

Publication number Publication date
EP2302063A3 (de) 2011-05-25
EP2302063B1 (de) 2016-05-04
CA2775218C (en) 2016-04-26
EP1446489A4 (de) 2006-09-06
US20080020441A1 (en) 2008-01-24
US20050222057A1 (en) 2005-10-06
JP2005505296A (ja) 2005-02-24
ES2584305T3 (es) 2016-09-27
EP2302063A2 (de) 2011-03-30
DK1446489T3 (da) 2012-05-14
WO2003033519A3 (en) 2003-09-25
AU2002347426B2 (en) 2007-05-10
CN102172406A (zh) 2011-09-07
WO2003033519A2 (en) 2003-04-24
US20120208866A1 (en) 2012-08-16
EP1446489B1 (de) 2012-01-18
HK1156069A1 (en) 2012-06-01
US20080188436A1 (en) 2008-08-07
CA2775218A1 (en) 2003-04-24
ES2380612T3 (es) 2012-05-16
PT1446489E (pt) 2012-04-24
CA2463631A1 (en) 2003-04-24
CN1599797A (zh) 2005-03-23
CN102172406B (zh) 2013-03-13
JP4458846B2 (ja) 2010-04-28
EP1446489A2 (de) 2004-08-18
PT2302063T (pt) 2016-07-28
CA2463631C (en) 2012-07-03

Similar Documents

Publication Publication Date Title
ATE541940T1 (de) Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
CN107384894B (zh) 功能化氧化石墨烯高效运载CRISPR/Cas9用于基因编辑的方法
JP6752234B6 (ja) Ｒｎａ分子の翻訳効率を高めるｕｔｒ
JP6959654B2 (ja) 新規の最小ｕｔｒ配列
PL415463A1 (pl) Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
TW200516144A (en) Novel bone mineralization proteins, DNA, vectors, expression systems
EP1100878B8 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
Padan et al. Site-specific mutagenesis of histidine residues in the lac permease of Escherichia coli.
DK0566732T3 (da) Adeno-associerede virus-2-basalvektorer
DE59702936D1 (de) Hantelförmige expressionskonstrukte für die gentherapie
DK0777732T3 (da) Modulatorer af kropsvægt, tilsvarende nukleinsyrer og proteiner og diagnostiske og terapeutiske anvendelser deraf
MX9701200A (es) Moduladores de peso del cuerpo, acidos nucleicos y proteinas correspondientes y sus usos en diagnostico y terapeuticos.
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
AU5728399A (en) Method for transformation of animal cells
ATE438727T1 (de) Optimierung von transgenexpression in säugetierzellen
DE3856240D1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
Liu et al. Mutational switching of a yeast tRNA synthetase into a mammalian-like synthetase cytokine
Mizuguchi et al. Cytoplasmic Gene Expression System Enhances the Efficiency of Cationic Liposome-Mediatedin VivoGene Transfer into Mouse Brain
JPS62265983A (ja) ヒト組織プラスミノ−ゲン活性化因子の微生物学的製造
RU2841956C1 (ru) Рекомбинантные плазмидные ДНК pCMV6_T7_synthUTR_AGN/GNN, кодирующие искусственные матричные РНК, обеспечивающие синтез белков в клетках млекопитающих
JP7708752B2 (ja) 細菌パスツレラ・ニューモトロピカ（Рａｓｔｅｕｒｅｌｌａ ｐｎｅｕｍｏｔｒｏｐｉｃａ）由来Ｃａｓ９タンパク質の使用
HK40084463B (zh) 来自细菌嗜肺巴斯德杆菌的cas9蛋白的用途
DE69922071D1 (de) Tumor-suppressorgen Del-27 und das dadurch kodierte Protein, verfahren zu deren Herstellung und Nutzung
KR20260025217A (ko) 신규한 합성 5'utr이 포함된 인공 핵산 분자 및 이의 용도